Skip to main content
Equibles
VXRT $0.32 +0.00%
VXRT logo
VXRT · Vaxart, Inc.
Track VXRT — free

Use VXRT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VXRT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.32 +0.00 (+0.00%) At close · Jul 8 Play latest call Q4 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“In the second quarter of 2026, management concluded that our cash, cash equivalents and investments are not sufficient to fund our planned operations for at least twelve months from the date of issuance of our financial statements, and these conditions raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Nov 5, 2026
Market Cap
$126.27M
Shares
243.70M
Volume · Jul 8 11.57M Avg daily vol (3M) 4.77M
All webcasts

Earnings call · FY2026 Q3

Vaxart, Inc. (VXRT) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $10.62M -85.3% YoY
Net income -$17.69M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 5, 2026
Vaxart expects COVID-19 trial efficacy and safety data from 400 participants and approximately 5,000 participants by mid-year 2027. Third-quarter 2026 revenue was $10.6 million, and net loss was $17.7 million.
10-Q report · filed Nov 5, 2026
Vaxart reported $65.5 million in cash, cash equivalents and short-term investments as of September 30, 2026, saying they would not fund at least 12 months of operations and raising substantial doubt about its going concern.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 5, 2026 10-Q report Filed Nov 5, 2026

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Government Contract$7.54M -89.6% YoY
Collaboration Revenue$2.92M
Non-Cash Royalty Revenue$154,000
Full-screen source Call document

VXRT alerts

Vaxart, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →

Embed Vaxart, Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview